Five-year overview

Income statement summary, SEK millions 2020 2019 2018 2017 2016
Operating income 2,382.2 2,140.7 2,367.0 2,470.1 2,341.4
Personnel expenses -1,587.0 -1,413.7 -1,460.8 -1,448.9 -1,453.7
Other external expenses -586.6 -556.1 -823.4 -950.3 -816.4
Depreciations and impairments -127.1 -92.6 -47.5 -46.1 -44.2
Participations in associated company earnings 2.3 1.2 0.8 0.3 0.4
Operating profit/loss 83.8 79.5 36.1 25.1 27.5
Net financial income/expense -34.0 -4.5 -6.0 -3.6 -5.3
Profit after net financial income/expense 49.8 75.0 30.1 21.5 22.2
Tax -17.3 -15.4 -13.9 -9.8 -8.2
Profit for the year from remaing operations 1) 32.5 59.6 16.2 11.7 14.0
Profit for the year from divested operations 252.5 18.0 - - -
Total remaning and divested operations 285.0 77.6 16.2 11.7 14.0
           
Balance sheet summary, SEK millions 2020 2019 2018 2017 2016
Intangible assets 912.9 836.8 606.3 565.5 554.4
Tangible assets 34.2 20.3 24.8 32.1 37.5
Rights of use 283.5 272.0 - - -
Financial assets 29.6 24.2 13.7 11.6 8.2
Deferred tax asset 20.9 44.1 36.5 40.1 39.4
Current receivables 621.1 764.2 679.2 747.6 656.0
Cash and cash equivalents 336.6 142 38.2 20.3 64.9
Total assets 2,238.9 2,103.6 1,398.7 1,417.2 1,360.4
           
Equity 1,156.2 930.2 707.3 746.4 552.2
Non-current liabilities 424.5 450.4 238.1 82.8 226.6
Current liabilities 658.2 723.0 453.3 588.0 581.6
Total liabilities and equity 2,238.9 2,103.6 1,398.7 1,417.2 1,360.4
           
Cash flow sheet summary, SEK millions, including Embriq to 31 August 2020 2020 2019 2018 2017 2016
Cash flow from operating activities 331.6 245.9 123.1 -41.4 41.2
Cash flow from investing activities 70.7 -317.6 -67.9 -66.7 -71.5
Cash flow from financing activities -206.4 176.9 -38.1 63.2 -19.9
Cash flow for the year 195.9 105.2 17.1 -44.9 -50.2
           
Alternative performance measures, including Embriq to 31 August 2020 2020 2019 2018 2017 2016
EBITA, SEK million 364.0 138.0 44.1 37.5 39.8
EBITA margin, % 13.9 5.4 1.9 1.0 1.2
Equity/assets ratio, % 51.6 44.2 50.6 52.0 40.6
Equity per share at the end of the period 58.73 47.25 39.10 40.77 41.50
Net indebtedness 213.8 405.5 119.8 167.2 244.2
Net debt / EBITDA, multiple 1.08 1.5 1.4 2.3 3.4
Return on equity, % 26.1 11.7 4.2 3.4 4.2
Return on capital employed, % 28.9 9.4 4.5 3.2 4.1
Debt/equity ratio, times 0.4 0.6 0.2 0.3 0.6
Organic growth, % -2.4 8.1 -3.8 4 10
Organic growth excluding exchange rate effects, % -2.2 8.2 -4 4 6
Earnings per share before dilution, SEK/share 14.48 4.19 0.85 0.71 1.03
Earnings per share after dilution, SEK/share 14.16 4.16 - - -
Average number of shares 19,687,909 18,487,909 18,087,909 16,417,744 12,921,721
Number of shares at the end of the period 19,687,909 19,687,909 18,087,909 18,087,909 12,921,721
Utilisation, % 76.0 76.8 77.1 75.2 73.0
Sales per full-time employee, SEK thousand 1,171 1,278 1,270 1,286 1,208
Operating profit per full-time employee, SEK thousand 163.4 52 19 13 14
Number of working days 252 249 248 249 251
Number of full-time employees 2,227 1,995 1,863 1,921 1,939
Number of employees at end of period 2,330 2,393 1,953 1,994 2,027
Dividend per share, SEK/share 0.00 1.5 1.00 0.50 0.00

1) 2020 and 2019, remaining operations after the divestment of Embriq